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Long non-coding RNA ATB promotes malignancy of
esophageal squamous cell carcinoma by regulating
miR-200b/Kindlin-2 axis
Zhongwen Li1,8, Xiaoliang Wu2,3,8, Ling Gu3,4,8, Qi Shen2, Wen Luo2, Chuangzhong Deng3, Qianghua Zhou3, Xinru Chen3, Yanjie Li5,
ZuanFu Lim6, Xing Wang3, Jiahong Wang*,3,7 and Xianzi Yang*,3,7
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer-related death, especially in China. In addition,
the prognosis of late stage patients is extremely poor. However, the biological significance of the long non-coding RNA lnc-ATB
and its potential role in ESCC remain to be documented. In this study, we investigated the role of lnc-ATB and the underlying
mechanism promoting its oncogenic activity in ESCC. Expression of lnc-ATB was higher in ESCC tissues and cell lines than that in
normal counterparts. Upregulated lnc-ATB served as an independent prognosis predictor of ESCC patients. Moreover, loss-of-
function assays in ESCC cells showed that knockdown of lnc-ATB inhibited cell proliferation and migration both in vitro and in vivo.
Mechanistic investigation indicated that lnc-ATB exerted oncogenic activities via regulating Kindlin-2, as the anti-migration role of
lnc-ATB silence was attenuated by ectopic expression of Kindlin-2. Further analysis showed that lnc-ATB functions as a molecular
sponge for miR-200b and Kindlin-2. Dysregulated miR-200b/Kindlin-2 signaling mediated the oncogenic activity of lnc-ATB in
ESCC. Our results suggest that lnc-ATB predicts poor prognosis and may serve as a potential therapeutic target for ESCC patients.
Cell Death and Disease (2017) 8, e2888; doi:10.1038/cddis.2017.245; published online 22 June 2017
Esophageal cancer has the eighth highest incidence rate
among all cancer types worldwide, with varying occurrences
from country to country.1,2 China is one of those countries with
highest risk of esophageal cancer.3 Esophageal squamous
cell carcinoma (ESCC) arising from the squamous epithelium
accounts for the most prevalent histological subtype.2 Despite
recent advances in diagnosis technologies such as endo-
scopic ultrasonography and wide application of chemora-
diotherapy combined with esophagogastric surgery in
ESCC,4,5 the overall survival of stage III patients is approxi-
mately 10–15% and o12 months for late stage patients.6
Therefore, new molecular biomarkers associated with tumor
development and prognosis prediction are urgently needed in
order to improve the understanding and outcome of this lethal
disease.
Cancer is fundamentally regarded as a genetic disease7
that alters cellular information flow leading to uncontrolled
proliferation and re-balanced cellular homeostasis.8,9 Recent
multiple genome-wide cancer studies have revealed an
extensive landscape of long non-coding RNAs (lncRNAs)
with exquisite regulation of the malignant transformation via
interaction with other cellular macromolecules.9,10 LncRNAs
are a group of transcripts longer than 200 nucleotides from
non-protein coding regions of the genome, the number of
which is estimated to outnumber that of the protein coding
genes.11 It is now recognized that lncRNAs may act as
molecular sponge and competitively suppress expression of
microRNAs (miRNAs).10,11 One such lncRNA is the lncRNA
activated by transforming growth factor β (TGF-β) (lnc-ATB),
which was located in human chromosome 14 with 2446
nucleotides in length (Supplementary Table 1). Lnc-ATB
contains multiple miR-200-binding sites and is known to be
the mediator for TGF-β-induced epithelial–mesenchymal
transition (EMT) in hepatocellular carcinoma.12 Moreover,
lnc-ATB could promote trastuzumab resistance and the
invasion-metastasis cascade in breast cancer by competi-
tively binding miR-200c and upregulating ZEB1 and ZNF-217,
resulting in EMT.13 Dysregulation of lnc-ATB have been
reported in human tumors including gastric,14 colorectal,15,16
brain,17 pancreatic18 and renal19 cancer. However, expression
of lnc-ATB in ESCC and the underlying mechanisms remain
unsolved.
Results
Lnc-ATB is upregulated in ESCC cancer tissues and cell
lines and predicts unfavorable prognosis of ESCC
patients. To define the role of lnc-ATB in ESCC, we
examined the expression level of Lnc-ATB in 150 paired
ESCC cancer and normal squamous epithelial tissues by
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qRT-PCR. We found that lnc-ATB was significantly upregu-
lated in ESCC cancer tissues compared with the matched
adjacent normal tissues (Figure 1a). Furthermore, expression
of Lnc-ATB was also determined in a panel ESCC cancer cell
lines (KYSE30, Eca109, Eca9706, KYSE510, KYSE520,
KYSE410, KYSE140 and KYSE150) and one immortalized
normal epithelial cells (NE1). The results showed that
lnc-ATB expression was upregulated in the ESCC cancer
cell lines when compared with NE1 cells (Figure 1b). We then
analyzed the correlation between Lnc-ATB expression and
the clinicopathological features of 150 ESCC patients. Using
the median expression level as the cutoff value, our patient
cohort was assigned into high lnc-ATB expression group
(above the median, n=75) and low lnc-ATB expression group
(below the median, n= 75) (Figure 1c). The correlations
between expression of Lnc-ATB and the clinical pathological
parameters of ESCC patients are summarized in Table 1.
To further analyze whether lnc-ATB expression could be a
potential prognosis predictor in ESCC patients, we performed
a Kaplan–Meier analysis with log-rank test. The results
showed that the median overall survival of patients with high
lnc-ATB expression was 20 months, whereas the median
overall survival for patients with low lnc-ATB expression was
51 months (Figure 1d). Moreover, expression of lncRNA
correlates with disease-free survival of ESCC patients
(P= 0.03, Figure 1e). Further univariate and multivariate
survival analyses showed that TNM stage (Po0.001) and
Lnc-ATB expression (P=0.023) were independent prognosis
Figure 1 Lnc-ATB is upregulated in ESCC cancer tissues and cell lines and predicts poor prognosis. (a) Expression of lnc-ATB in 150 paired ESCC cancer tissues and
adjacent normal tissues was detected by qRT-PCR and was normalized to that of GAPDH. Expression level of lnc-ATB was presented as △cycle threshold (△Ct) in tumor
tissues relative to normal tissues. (b) Expression of lnc-ATB in ESCC cancer cells including KYSE30, Eca109, Eca9706, KYSE510, KYSE520, KYSE410, KYSE140 and
KYSE150 and the normal epithelial cell line NE1 was detected by qRT-PCR. Expression level of lnc-ATB was analyzed with the 2△△Ct method and normalized to that of NE1.
(c) Expression of lnc-ATB in 150 ESCC cancer tissues was detected by qRT-PCR. Expression level of lnc-ATB was presented as log2 fold change of△Ct value in tumor tissues to
that of corresponding normal tissues. ESCC patients were divided into high lnc-ATB group (n= 75) and low lnc-ATB group (n= 75) according to the median value. (d) Kaplan–
Meier curves of overall survival based on lnc-ATB expression in all 150 patients (P= 0.016, log-rank test). (e) Kaplan–Meier curves of disease-free survival based on lnc-ATB
expression in all 150 patients (P= 0.03, log-rank test). For all quantitative results, the data are presented as the mean± S.E.M. from three independent experiments. *Po0.05
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indicators of ESCC patients (Table 2). Collectively, lnc-ATB is
upregulated in ESCC and predicts poor prognosis of patients.
Knockdown of lnc-ATB inhibits proliferation and induces
cell cycle arrest of ESCC cells. To explore the functional
relevance of dysregulated lnc-ATB in ESCC, KYSE30 and
Eca109 cells were selected for further analysis. Isolation of
cytoplasmic and nuclear RNAs indicated that lnc-ATB was
mainly located in the cytoplasm (Supplementary Figure 1).
Lentivirus stably expressing short hairpin RNAs targeting
lnc-ATB (sh#1 and sh#2), as well as the scramble sequence
(NC) were introduced into ESCC cells and qRT-PCR analysis
confirmed effective knockdown of lnc-ATB in KYSE30 and
Eca109 cells (Figure 2a). CCK-8 assays revealed that
knockdown of lnc-ATB significantly decreased cell viability
of ESCC cell lines (KYSE30 and Eca109) (Figure 2b). On the
other hand, KYSE30 and Eca109 cells with relative high lnc-
ATB expression showed faster proliferation rate than that of
KYSE140 and KYSE410 cells with low lnc-ATB expression
(Supplementary Figure 2A). Moreover, knockdown of lnc-ATB
significantly suppressed formation of colonies compared with
sh-control group in KYSE30 and Eca109 cells (Figure 2c).
We then investigated whether the anti-proliferation roles of
lnc-ATB knockdown was associated with cell cycle arrest or
increased apoptosis. To this end, KYSE30 and Eca109 cells
(sh#1, sh#2 and negative control (NC)) were subjected to cell
cycle and cell apoptosis analysis by flow cytometry. As shown
in Figure 2d and Supplementary Figure 2B, knockdown of
lnc-ATB significantly induced G2/M phase arrest and
apoptosis in KYSE30 and Eca109 cells.
Knockdown of lnc-ATB inhibits migration and lung
metastasis of ESCC cells. We then sought to investigate
migratory and invasive capacity of ESCC cells after knock-
down of lnc-ATB. ESCC cells with lnc-ATB reduction had a
significant decrease in cell migration (Figure 3a). EMT has
vital roles in cancer metastasis.20 Western blot analysis
revealed that knockdown of lnc-ATB led to elevated expres-
sion of the epithelial markers including E-cadherin and
β-catenin and decreased expression of the mesenchymal
marker N-cadherin (Figures 3b and c), indicating that EMT
may be associated with the pro-metastasis effects of lnc-ATB
in ESCC. We then injected Eca109 cells with lnc-ATB
suppression into the tail vein of nude mice and found that
the metastatic nodules in the lung were significantly
decreased in the knockdown group compared with that in
the control group (Figures 3d and e).
Correlation of expression of Lnc-ATB with miR-200b.
Previous studies have reported that many lncRNAs function
as a competing endogenous RNAs (ceRNA) to bind disease
specific miRNAs such as the case of lnc-ATB and miR-200
family in hepatocellular carcinoma12 and glioma.17 To
examine whether lnc-ATB acts in a similar manner, prediction
of miRNA target sites in starbase (http://starbase.sysu.edu.
cn/) was performed. We found multiple miR-200b-binding
sites in lnc-ATB (Figure 4a) and further RNA immunopreci-
pitation (RIP) analysis confirmed that miR-200b was sig-
nificantly enriched with lnc-ATB (Supplementary Figure 3).
Moreover, tumor-suppressive roles of miR-200b have been
reported in several human cancers including ESCC,21,22 so
we focused on miR-200b as the primary candidate. We found
that expression of miR-200b was remarkably increased after
Table 1 The correlation between clinicopathological parameters and lnc-ATB
expression
Lnc-ATB expression
Low, n (%) High, n (%)
Age
o60 44 (58.7) 39 (52.0) 0.511
⩾60 31 (41.3) 36 (48.0)
Gender
Male 61 (81.3) 57 (76.0) 0.550
Female 14 (18.7) 18 (24.0)
Alcohol consumption
Ever and current 52 (69.3) 47 (62.7) 0.491
Never 23 (30.7) 28 (37.3)
Smoking status
Ever and current 44 (58.7) 43 (57.3) 1.000
Never 31 (41.3) 32 (42.7)
Tumor size
o5 cm 63 (84.0) 62 (82.7) 1.000
⩾5 cm 12 (16.0) 13 (17.3)
Differentiation status
Well or moderate 59 (78.7) 59 (78.7) 1.000
Poor 16 (21.3) 16 (21.3)
TNM stage 0.514
I–II 41 (54.7) 36 (48.0)
III 34 (45.3) 39 (52.0)
Table 2 Univariate and multivariate analyses of various potential prognostic factors in ESCC patients
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age (o60 /⩾60) 1.43 (0.92–2.24) 0.112 — —
Gender (male/female) 0.92 (0.54–1.56) 0.757 — —
Alcohol (never/ever) 0.98 (0.61–1.58) 0.921 — —
Smoke (never/ever) 0.96 (0.61–1.50) 0.842 — —
Tumor size (⩾5 cm/o5 cm) 1.48 (0.84–2.60) 0.176 — —
Differentiation (moderate/poor, well) 1.49 (0.90–2.47) 0.118 — —
TNM stage (III/I–II) 3.65 (2.25–5.92) 0.000 3.59 (2.21–5.83) 0.000
lnc-ATB (high/low) 1.76 (1.22–2.76) 0.014 1.69 (1.07–2.66) 0.023
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knockdown of lnc-ATB (Figure 4b). Next, we constructed
luciferase reporters, which contain wild-type (WT) or mutated
(Mut) miR-200b-binding sites, for direct binding validations
(Figure 4c). As shown in Figure 4d, miR-200b mimics
significantly reduced the luciferase activities of the WT
reporter vector but did not affect the activity of the mutant
Figure 2 Knockdown of Lnc-ATB inhibits proliferation and induces cell cycle arrest of ESCC cells. (a) Expression of lnc-ATB was detected in KYSE30 and Eca109 cells after
treatment with indicated short hairpin RNAs, whereas sh#1 and sh#2 indicates two independent oligonucleotides targeting lnc-ATB. (b) CCK-8 assays of KYSE30 and Eca109
cells after knockdown of lnc-ATB. (c) Colony formation assays of KYSE30 and Eca109 cells after knockdown of lnc-ATB. (d) Cell cycle assays of KYSE30 and Eca109 cells after
knockdown of lnc-ATB. For all quantitative results, the data are presented as the mean± S.E.M. from three independent experiments. *Po0.05
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vector compared with miR-NC, supporting the notion that
miR-200b bind bona fide to lnc-ATB. Moreover, miR-200b
was significantly upregulated in ESCC cell lines with relative
low lnc-ATB expression than cell lines with high expression
(Figure 4e). Expression of miR-200b and lnc-ATB showed an
inverse correlation pattern in our patient cohort (Figure 4f),
providing clues that lnc-ATB may function as ceRNA for
miR-200b.
Modulation of Kindlin-2 by lnc-ATB. Decreased expres-
sion of miR-200b was reported to predict poor prognosis of
ESCC patients and create malignant phenotype via modula-
tion of Kindlin-2.21,22 We found that miR-200b could bind to
the 3′-UTR of Kindlin-2 and modulate expression of Kindlin-2
in KYSE30 and Eca109 cells (Figures 5a–c). Moreover,
expression of Kindlin-2 was suppressed in KYSE30 and
Eca109 cells after knockdown of lnc-ATB (Figure 5d). qRT-
PCR analysis indicated that mRNA level of Kindlin-2 was
decreased by lnc-ATB knockdown (Figure 5e). Kindlin-2 was
previously reported to be involved in the cytoskeleton shaping
via RhoA/FAK signaling. Immunoblotting showed that active
RhoA and phosphorylated FAK was suppressed after
knockdown of lnc-ATB (Figure 5f).
miR-200b/Kindlin-2 mediates oncogenic activity of
lnc-ATB. To determine whether miR-200b/Kindlin-2 mediated
oncogenic effects of lnc-ATB in ESCC, KYSE30 and Eca109
cells with stable lnc-ATB reduction were transfected with
miR-200b inhibitors or a vector with the coding sequence of
Kindlin-2 lacking the 3′-UTR (pcDNA-Kindlin-2). We found that
miR-200b inhibitors or pcDNA-Kindlin-2 significantly increased
mRNA and protein levels of Kindlin-2 (Figures 6a and b).
Moreover, attenuation of Kindlin-2 significantly reversed the
anti-migration roles of lnc-ATB knockdown (Figure 6c).
Knockdown of Lnc-ATB significantly suppressed tumor
growth in vivo. To investigate whether lnc-ATB regulates
ESCC tumorigenesis in vivo, Eca109 cells (sh#1, sh#2 and
Figure 3 Knockdown of Lnc-ATB decreased migration and suppressed lung metastasis of ESCC. (a) The representative pictures and quantification of cell migration across
the membrane in KYSE30 and Eca109 cells with lnc-ATB reduction. (b) The protein expression of E-Cadherin, N-Cadherin and β-Catenin in KYSE30 and Eca109 cells with stable
lnc-ATB reduction were evaluated by western blotting. GAPDH was used for normalization. (c) mRNA level of E-Cadherin in KYSE30 and Eca109 cells with stable lnc-ATB
reduction was detected. (d) The nodules in the lung were numbered (n= 6). (e) Visualization of HE-stained lung sections are shown. Scale bars: 100 μm. For all quantitative
results, the data are presented as the mean± S.E.M. from three independent experiments. *Po0.05
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NC) were subcutaneously injected into the dorsal flank of
female nude mice and the tumor volume was monitored. As
shown in Figures 7a–c, the volume and weight of xenografts in
the knockdown groups were significantly smaller compared
with those formed in NC group, which is consistent with in vitro
results. Tumor weight was significantly reduced in the knock-
down group than that in the control group (Figure 7c).
Moreover, qRT-PCR analysis of the dissected xenografts from
the knockdown group showed decreased expression of
lnc-ATB and increased expression of miR-200b than that from
control group (Figures 7d and e). Immunostaining of Ki-67 and
Kindlin-2 in dissected tumors showed that silencing of lnc-ATB
inhibited proliferation and Kindlin-2 of ESCC cells (Figures
7f–h), indicating that knockdown of lnc-ATB significantly
suppressed tumor growth via miR-200b/Kindlin-2 in vivo.
Discussion
ESCC constitutes the main histopathological subtype of
esophageal cancer occurring in the central regions of
China.3 The overall prognosis of ESCC remains unsatisfactory
despite recent progression in diagnostic methods and
therapeutic alternatives.1,2,4,5 To improve the survival rate of
ESCC patients, a better understanding of the genetic and/or
epigenetic alterations underlying tumorigenesis and metas-
tasis of ESCC is urgently required. Dysregulation of lncRNAs
has been previously reported in a wide range of human
cancers including ESCC.10,11,14,17,19,23–25 For example, the
lncRNA MALAT1,23,25 HOTTIP26 and HOTAIR27 were over-
expressed in ESCC tumor tissues and are good predictive
factors for overall survival. Moreover, increased expression of
lnc-ATBwas observed in breast cancer,13 gastric cancer14 and
Figure 4 Correlation between expression levels of Lnc-ATB and miR-200b. (a) Diagram showing binding site in lnc-ATB of miR-200b. (b) Expression of miR-200b in KYSE30
and Eca109 cells after transfection with mimics or inhibitor. (c) Expression of miR-200b in KYSE30 and Eca109 cells with lnc-ATB reduction. (d) Luciferase assays of KYSE30 and
Eca109 cells after transfection with WTor mutant reporter vector and miR-200b mimic. (e) Expression of miR-200b in the ESCC cancer cell lines. (f) Expression of miR-200b of
lnc-ATB in the ESCC tumor samples. For all quantitative results, the data are presented as the mean± S.E.M. from three independent experiments. *Po0.05
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colorectal cancer,15,16 indicating that lnc-ATB may function as
oncogenes in these cancers. Inspired by these observations,
we sought to determine the role of lnc-ATB in ESCC. We were
able to detect lnc-ATB in 150 ESCC tumor tissues and paired
normal counterparts and draw correlations between the
expression of lnc-ATB with clinicopathological parameters.
Our data revealed that lnc-ATB was significantly upregulated
in ESCC tumor tissues and patients with high lnc-ATB
expression showed poorer prognosis than those with low
expression. Expression of lnc-ATB was associated with tumor
invasion, lymph node metastasis and differentiation state in
ESCC. This was validated in our current study, in which
elevated lnc-ATB expression was positively correlated with
ESCC carcinogenesis. However, Qu et al.18 reported that
expression of lnc-ATB decreased in pancreatic cancer tissues
and cell lines, and decreased lnc-ATB expression was an
independent predictor of poor prognosis in pancreatic cancer
patients. Overall, these data suggest that there is a cancer
specific expression pattern of lnc-ATB.
Previous studies have indicated that knockdown of
lnc-ATB inhibited EMT and cell invasion in hepatocellular
carcinoma12 and colorectal cancer16 in vitro as well as
tumor growth in the nude mice. We therefore proceeded to
evaluate the biological roles of lnc-ATB in ESCC by short
hairpin RNA-mediated loss-of function assays. Silencing of
lnc-ATB expression significantly suppressed proliferation and
migration of ESCC cells compared with control. EMT is a
critical process associated with tumor progression and
metastasis. Our data showed that knockdown of lnc-ATB
downregulated Vimentin and N-cadherin and upregulated
E-cadherin. These findings demonstrate that lnc-ATB may
have a role in EMT.
Tumor-suppressive effects of miR-200 family has been
repeatedly verified during the past few years,21,22,28,29
whereby miR-200c initiates malignant transformation by
modulation of cancer stem cells,30 and decreased miR-200
promotes distant metastasis via regulation of the EMT
activator ZEB1 and ZEB2.31 Moreover, chr1p36 containing
Figure 5 Lnc-ATB regulates expression of Kindlin-2. (a) Diagram showing binding site in Kindlin-2 of miR-200b. (b) Luciferase assays in cells transfected with WTor mutant
3′-UTR reporter vector and miR-200b mimic or inhibitor. (c) Immunoblotting of Kindlin-2 in KYSE30 and Eca109 cells transfected with miR-200b mimic or inhibitor. GAPDH was
used for normalization. (d) Immunoblotting of Kindlin-2 in KYSE30 and Eca109 cells with lnc-ATB reduction. GAPDH was used for normalization. (e) Relative mRNA level of
Kindlin-2 in KYSE30 and Eca109 cells with lnc-ATB reduction. (f) Immunoblotting of RhoA-GTP and p-FAK in KYSE30 and Eca109 cells following lnc-ATB reduction. GAPDH was
used for normalization. For all quantitative results, the data are presented as the mean±S.E.M. from three independent experiments. *Po0.05
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the miR-200b cluster is often deleted in ESCC.32 Over-
expression of miR-200b induces cell cycle arrest and
represses cell growth, migration and invasion of ESCC
cells.21,22 Our results showed that expression of miR-200b
was significantly upregulated after knockdown of lnc-ATB, and
further dual luciferase assays confirmed direct binding of lnc-
ATB and miR-200b.
Cells with dynamic assembly of cytoskeleton and active
focal adhesion with the surrounding microenvironment are
predisposed to local invasion and distant metastasis.33
Kindlin-2, a FERM domain containing protein, has been
shown to modulate cell migration via interactions with the
cytoskeleton, resulting in cell–extracellular matrix adhesions
in human cancers including ESCC.21,22,34–37 Furthermore,
Figure 6 Kindlin-2 mediates the oncogenic activity of lnc-ATB. (a) Relative mRNA level of Kindlin-2 in KYSE30 and Eca109 cells following lnc-ATB suppression and
transfection with miR-200b inhibitor or a pcDNA-Kindlin-2 lacking the 3′-UTR. (b) Immunoblotting of Kindlin-2 in KYSE30 and Eca109 cells following lnc-ATB suppression and
transfection with miR-200b inhibitor or a pcDNA-Kindlin-2 lacking the 3′-UTR. GAPDH was used for normalization. (c) The representative pictures and quantification of cell
migration across the membrane in KYSE30 and Eca109 cells following lnc-ATB suppression and transfection with miR-200b inhibitor or a pcDNA-Kindlin-2 lacking the 3′-UTR.
For all quantitative results, the data are presented as the mean±S.E.M. from three independent experiments. *Po0.05
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overexpression of Kindlin-2 was observed in the invasive front
of malignant mesothelioma38 and breast cancer,35 whereas
knockdown of Kindlin-2 exerts tumor-suppressive roles.
Upregulation of Kindlin-2 induced by decreased miR-200b
promotes malignant phenotype of ESCC and predicts
unfavorable prognosis.21,22 In this study, we found that
overexpression of lnc-ATB may function as molecular sponge
of Kindlin-2 and miR-200b. Attenuation of the anti-proliferative
roles of lnc-ATB knockdown by re-induction of Kindlin-2 in
ESCC cells further demonstrated the role of the lnc-ATB/
miR-200b/Kindlin-2 axis in tumor metastasis. Notably,
this mechanism may correlate with our clinical observations
that the loss of miR-200b in ESCC tumors is associated with
lymph node metastasis, advanced clinical stage and short
survival.
Conclusions
Our current study demonstrates that upregulation of lnc-ATB is
associated with ESCC progression. Our results provide new
insights into the dysregulated lnc-ATB/miR-200b/Kindlin-2
axis in the development of ESCC and suggest that lnc-ATB
represent a potential therapeutic target for ESCC.
Materials and Methods
Patients and samples. The ESCC tumor tissues and corresponding normal
esophageal epithelial tissues were obtained from 150 patients who underwent
surgery at the Sun Yat-sen University Cancer Center from 2007 to 2009,
Guangzhou, China. No patients enrolled in our study were given local or systemic
treatment before surgery. Clinicopathological data were collected from medical
records. All specimens were snap-frozen immediately after resection from the
patient and stored at − 80 °C until RNA extraction.
Figure 7 Lnc-ATB suppresses tumor growth via miR-200b/Kindlin-2 in vivo. (a) Tumor growth curve formed by the indicated cells. (b) Tumors formed in the nude mice were
photographed. (c) Tumor weight of mice in the NC, sh#1 and sh#2 groups were recorded. The expression levels of lnc-ATB (d) and miR-200b (e) in the dissected tumors were
measured. (f) Immunohistochemical staining of Ki-67 and Kindlin-2 in the xenograft tumors. Scale bars: 50 μm. (g) Quantitative analysis for immunostaining of Ki-67 (g) and
Kindlin-2 (h) in the xenograft tumors. For all quantitative results, the data are presented as the mean±S.E.M. from three independent experiments. *Po0.05
LncRNA ATB predicts poor prognosis in esophageal carcinoma
Z Li et al
9
Cell Death and Disease
Cell lines and cell culture. The human ESCC cell lines (KYSE150,
KYSE140, KYSE410, KYSE520, KYSE510, Ec109, Ec9706 and KYSE30) were
obtained either from the Cell Bank of the Chinese Academy of Sciences (Shanghai,
China) or purchased from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen (DSMZ, Braunschweig, Germany). The human embryonic kidney cell
line HEK293a were purchased from the American Type Culture Collection
(Manassas, VA, USA). All cells were cultured in Dulbecco’s modified essential
medium supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT,
USA), 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO, USA) and 100 μg/ml
streptomycin (Sigma-Aldrich) and maintained in a humidified incubator at 37 °C
with 5% CO2.
RNA extraction and quantitative real-time PCR. Total RNAs from cell
lines and tissue samples was extracted using Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. Cytoplasmic and nuclear RNA
were isolated with the commercial kit (NORGEN, Thorold, ON, Canada) according
to the manufacturer’s instructions. RNA concentration and quality were evaluated by
the 260/280 nm absorbance with a Nanodrop Spectrophotometer (IMPLEN GmbH,
Munich, Germany). The RNA was then reversely transcribed to cDNA with the
PrimeScript RT Master Mix (Takara Biotechnology, Dalian, China). SYBR Green Mix
(Promega, Madison, WI, USA) was used to detect expression of lnc-ATB and




Kindlin-2 forward: 5′- TGTCTCCCCGCTATCTAAAAAAGT-3′
Kindlin-2 reverse: 5′- TGATGGGCCTCCAAGATTCT-3′
E-Cadherin forward: 5′- CGAGAGCTACACGTTCACGG-3′
E-Cadherin forward: 5′- GGGTGTCGAGGGAAAAATAGG-3′
GAPDH forward: 5′- GCAAGAGCACAAGAGGAAGA-3′
GAPDH reverse: 5′-ACTGTGAGGAGGGGAGATTC-3′.
For measurement of miRNAs, TaqMan MicroRNA Assay kits (Applied Biosystems,
Darmstadt, Germany) were used and real-time PCR reaction was carried out using
ABI 7500 fast real-time PCR system (Applied Biosystems). U6 served as the internal
control. PCR cycling conditions were 10 min at 95 °C followed by 45 cycles of 95 °C
for 15 s and 60 °C for 60 s. All reactions were performed in triplicates. The fold
change for each gene relative to the control group was calculated using the 2−ΔΔCt
method.
Cell transfection. Lentivirus containing the short hairpin RNA targeting human
lnc-ATB (Supplementary Table 2) was obtained from GenePharma (Shanghai,
China), and was labeled as sh#1, sh#2 and its corresponding non-targeting
sequence (sh#NC). The ESCC cells were transfected with the lentivirus before they
were selected with puromycin (3 μg/ml) for 72 h and the efficiency was confirmed
by GFP-positive cells percentage. The miR-200b mimics, miR-200b inhibitors and
miR-200b NC were obtained from Ribobio (Guangzhou, China), and transfected into
the ESCC cell lines by using Lipofectamine2000 (Invitrogen) according to the
manufacturer’s protocol.
Cell proliferation, cell cycle and cell apoptosis assays. The
proliferation of ESCC cells was detected by the Cell Counting Kit-8 (CCK-8,
Beyotime Institute of Biotechnology, Jiangsu, China). Briefly, cells were placed into
96-well plates at the density of 1000 cells per well before addition of CCK-8 and the
absorbance was measured at a wavelength of 450 nm. Five replicates were
conducted for cells in each group and the experiments were repeated three times.
For the clone formation assay, cells transfected with the indicated lentivirus were
seeded in six-well plates in triplicates at a density of 500 cell per well and incubated
at 37 °C with 5% FBS for 14 days. The cells were fixed with 4% polyoxymethylene
and stained with 1.5% methylene blue. The colonies were counted and analyzed by
Image J software (NIH, Bethesda, MD, USA). For cell cycle analysis, the indicated
cells were collected, rinsed with cold PBS twice, and labeled with propidium iodide
(PI) solution (BD Cycletest Plus DNA Kit, San Jose, CA, USA). For cell apoptosis
analysis, Annexin V/PI kits (KeyGEN, Nanjing, China) were used to detect apoptotic
cells. The cells were then analyzed by a fluorescence-activated cell sorter according
to a previous report.21
Cell migration assays. The Corning Polycarbonate Membrane Insert
transwell chambers (Product #3422, Corning Costar Corp, Cambridge, MA, USA)
were used to perform migration assays. Briefly, cells (1 × 105) in serum-free media
were placed into the upper chamber and medium containing 20% FBS functioning
as a chemoattractant was placed in the lower chamber. After 36-h incubation, cells
were fixed with 4% polyoxymethylene and stained with 1.5% methylene blue. The
cells remaining in the upper chamber were removed with cotton swabs and those
migrated or invaded cells were imaged and counted under the microscope.
Experiments were independently repeated three times.
Western blot analysis. Total lysates were obtained from harvested ESCC
cells with the 1 × RIPA buffer (Cell Signaling Technology, Danvers, MA, USA)
supplemented with protease inhibitors. The concentration was determined by the
BCA Protein Assay kit (Pierce, Rockford, IL, USA) and identical quantities of
proteins (20–30 μg) were separated by SDS-polyacrylamide gel electrophoresis.
The proteins were then transferred to PVDF membranes. After blocking with 5%
non-fat milk in TBST, the membranes were probed with the indicated primary
antibodies at 4 °C overnight with gentle shaking. The membranes were then
exposed to the corresponding secondary antibody and the SupreSignal ECL Kit
(Pierce) was used to detect bands, with GAPDH as the internal control. The primary
antibodies used in our study include E-cadherin (1:500), Vimentin (1:500), β-catenin
(1:500, Cell Signaling Technology), Kindlin-2 (1:2000, Millipore, Bedford, MA, USA)
p-FAK(Tyr397) (1:1000, Cell Signaling Technology), FAK (1:500, Cell Signaling
Technology), active RhoA (1:500, Cell Signaling Technology), total RhoA (1:500,
Cell Signaling Technology) and GAPDH (1:5000, Sigma, Sigma-Aldrich, St. Louis,
MO, USA). HRP-conjugated goat anti-rabbit or anti-mouse IgG antibody (Abcam,
Cambridge, MA, USA) was used as the secondary antibody.
Luciferase reporter assay. The cDNA encoding lnc-ATB was amplified by
the Pfu Ultra II Fusion HS DNA Polymerase (Stratagene, Agilent Technologies,
Santa Clara, CA, USA) and sub-cloned into the HindIII and EcoRI sites of pcDNA3.1
vector (Invitrogen), named pcDNA3.1-ATB-WT. The pcDNA3.1-ATB-Mut vector,
which contains point mutations in the miR-200b response elements was generated
with a Quick Change Site-Directed Mutagenesis kit (Stratagene, Agilent
Technologies). The miR-200b targeting region at the 3′ end of either pcDNA3.1-
ATB-WT or pcDNA3.1-ATB-Mut was PCR-amplified and sub-cloned into the pmir-
GLO vector (Promega) using the one step directed cloning kit (Novoprotein,
Shanghai, China), which were named as lncRNA-ATB-WT or lncRNA-ATB-Mut,
respectively. The primers used for vector construction was provided in
Supplementary Table 3. Dual luciferase reporter assays were performed by co-
transfection in the indicated cell lines with pmir-GLO-lnc-ATB or pmir-GLO-lnc-ATB-
Mut vectors, and miR-200b mimics or miR-NC. At 48 h post-transfection, the
luciferase activities were measured with the Dual Luciferase Reporter Assay
System (Promega) according to the manufacturer instructions. Data are presented
as ratios between firefly and Renilla fluorescence activities. Each experiment were
performed independently in triplicates.
RIP assays. RIP assays were conducted with a Magna RNA-binding protein
immunoprecipitation kit (Millipore) according to the manufacturer’s instructions. Briefly,
cell lysates were incubated with RIP buffer containing magnetic beads conjugated with
negative IgG or anti-Ago2 antibody. Immunoprecipitated RNAs were obtained by
digestion with Proteinase K. Then, the extracted RNAs were reversely transcribed into
complementary DNA and subjected to quantitative real-time PCR analysis.
Animal work. Four-week female BALB/c mice were maintained in laminar
airflow chambers under specific pathogen-free conditions. The indicated cells were
suspended in cold PBS at a final concentration of 1 × 107 cells/ml, whereas 100 μl
of suspended cells was subcutaneously injected into the right flank of each mouse
(n= 5 per group). The tumor volume was monitored every 2 days and calculated
with the formula: 0.5 × length × width2. At 24 days post injection, the mice were killed
by cervical dislocation. The dissected tumors were weighed and paraffin embedded
for immunohistochemical analysis of Ki-67 expression. For the metastasis model,
the Eca109 cells with lnc-ATB reduction were injected into the tail vein of nude mice
(n= 6 per group). Eight weeks post injection, the mice were killed and the lungs
were removed and paraffin embedded. Consecutive sections (4 μm) were made
and stained with haematoxylin–eosin. The micrometastases in the lungs were
examined and counted. This study was carried out strictly in accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The experimental protocols were approved by the
committee on animal experimentation of the Sun Yat-sen University Cancer Center.
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Statistical analysis. All statistical analyses were performed using the SPSS 19.0
statistical software package (SPSS, Chicago, IL, USA). The data are representative of
three independent experiments and are presented as mean value±S.D. To evaluate
significant differences between two independent groups of samples, Student’s t-test was
used. The Kaplan–Meier method was used to generate the survival curve and
compared using the log-rank test. The chi-square test or Fisher’s exact test was used to
analyze the association of lnc-ATB expression with clinicopathological parameters.
P-value o0.05 was considered to be statistically significant.
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